Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $234.72 billion. The enterprise value is $260.40 billion.
| Market Cap | 234.72B |
| Enterprise Value | 260.40B |
Important Dates
The last earnings date was Thursday, July 17, 2025, before market open.
| Earnings Date | Jul 17, 2025 |
| Ex-Dividend Date | Mar 12, 2025 |
Share Statistics
Novartis AG has 1.94 billion shares outstanding. The number of shares has decreased by -3.37% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.94B |
| Shares Change (YoY) | -3.37% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.84B |
Valuation Ratios
The trailing PE ratio is 17.19 and the forward PE ratio is 14.21.
| PE Ratio | 17.19 |
| Forward PE | 14.21 |
| PS Ratio | 4.25 |
| Forward PS | 8.32 |
| PB Ratio | 5.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.15 |
| P/OCF Ratio | 11.29 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.06, with an EV/FCF ratio of 13.48.
| EV / Earnings | 19.07 |
| EV / Sales | 4.72 |
| EV / EBITDA | 11.06 |
| EV / EBIT | 13.58 |
| EV / FCF | 13.48 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.78.
| Current Ratio | 0.82 |
| Quick Ratio | 0.50 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 1.69 |
| Interest Coverage | 17.47 |
Financial Efficiency
Return on equity (ROE) is 32.49% and return on invested capital (ROIC) is 16.47%.
| Return on Equity (ROE) | 32.49% |
| Return on Assets (ROA) | 11.88% |
| Return on Invested Capital (ROIC) | 16.47% |
| Return on Capital Employed (ROCE) | 26.39% |
| Revenue Per Employee | $727,251 |
| Profits Per Employee | $179,935 |
| Employee Count | 75,883 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.17 |
Taxes
In the past 12 months, Novartis AG has paid $1.97 billion in taxes.
| Income Tax | 1.97B |
| Effective Tax Rate | 12.62% |
Stock Price Statistics
The stock price has increased by +8.78% in the last 52 weeks. The beta is 0.55, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +8.78% |
| 50-Day Moving Average | 118.35 |
| 200-Day Moving Average | 109.57 |
| Relative Strength Index (RSI) | 59.24 |
| Average Volume (20 Days) | 2,049,544 |
Short Selling Information
The latest short interest is 4.38 million, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 4.38M |
| Short Previous Month | 4.06M |
| Short % of Shares Out | 0.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.27 |
Income Statement
In the last 12 months, Novartis AG had revenue of $55.19 billion and earned $13.65 billion in profits. Earnings per share was $6.85.
| Revenue | 55.19B |
| Gross Profit | 42.10B |
| Operating Income | 19.18B |
| Pretax Income | n/a |
| Net Income | 13.65B |
| EBITDA | 23.55B |
| EBIT | 19.18B |
| Earnings Per Share (EPS) | $6.85 |
Balance Sheet
The company has $6.73 billion in cash and $32.64 billion in debt, giving a net cash position of -$25.91 billion or -$13.38 per share.
| Cash & Cash Equivalents | 6.73B |
| Total Debt | 32.64B |
| Net Cash | -25.91B |
| Net Cash Per Share | -$13.38 |
| Equity (Book Value) | 42.05B |
| Book Value Per Share | 21.69 |
| Working Capital | -5.78B |
Cash Flow
In the last 12 months, operating cash flow was $20.79 billion and capital expenditures -$1.46 billion, giving a free cash flow of $19.32 billion.
| Operating Cash Flow | 20.79B |
| Capital Expenditures | -1.46B |
| Free Cash Flow | 19.32B |
| FCF Per Share | $9.98 |
Margins
Gross margin is 76.28%, with operating and profit margins of 34.76% and 24.74%.
| Gross Margin | 76.28% |
| Operating Margin | 34.76% |
| Pretax Margin | 28.28% |
| Profit Margin | 24.74% |
| EBITDA Margin | 42.68% |
| EBIT Margin | 34.76% |
| FCF Margin | 35.02% |
Dividends & Yields
This stock pays an annual dividend of $2.60, which amounts to a dividend yield of 2.14%.
| Dividend Per Share | $2.60 |
| Dividend Yield | 2.14% |
| Dividend Growth (YoY) | 6.80% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 37.90% |
| Buyback Yield | 3.37% |
| Shareholder Yield | 5.51% |
| Earnings Yield | 5.82% |
| FCF Yield | 8.23% |
Analyst Forecast
The average price target for Novartis AG is $123.67, which is 2.04% higher than the current price. The consensus rating is "Hold".
| Price Target | $123.67 |
| Price Target Difference | 2.04% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 3.29% |
| EPS Growth Forecast (5Y) | 12.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.73 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.73 |
| Piotroski F-Score | 6 |